Lantern Pharma (LTRN) to Release Earnings on Thursday

Lantern Pharma (NASDAQ:LTRN) will likely be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Lantern Pharma to post earnings of ($0.44) per share for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Friday, November 14, 2025 at 12:00 AM ET.

Lantern Pharma (NASDAQ:LTRN) last announced its earnings results on Wednesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.13. On average, analysts expect Lantern Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Lantern Pharma Price Performance

Shares of Lantern Pharma stock opened at $3.63 on Wednesday. The firm’s fifty day simple moving average is $4.13 and its 200-day simple moving average is $3.88. The stock has a market capitalization of $39.20 million, a price-to-earnings ratio of -2.04 and a beta of 1.52. Lantern Pharma has a 12 month low of $2.55 and a 12 month high of $6.12.

Analyst Ratings Changes

A number of equities analysts have recently commented on LTRN shares. Wall Street Zen cut shares of Lantern Pharma from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lantern Pharma in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Lantern Pharma has an average rating of “Hold” and an average price target of $25.00.

Hedge Funds Weigh In On Lantern Pharma

An institutional investor recently bought a new position in Lantern Pharma stock. XTX Topco Ltd bought a new position in shares of Lantern Pharma Inc. (NASDAQ:LTRN) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 12,624 shares of the company’s stock, valued at approximately $40,000. XTX Topco Ltd owned approximately 0.12% of Lantern Pharma as of its most recent filing with the SEC. Institutional investors own 28.62% of the company’s stock.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.